ArticleBMC cancer2018
Impact of diabetes mellitus on epithelial ovarian cancer survival.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Trial
- Subtype-Specific Causal Effects of Antidiabetic Drug Targets on Ovarian Cancer: Mendelian Randomization and Colocalization Evidence.International journal of women's health · 2026Article
- Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus.Endocrine · 2025Review
- Pre-treatment nutrition-related indicators and the prognosis of patients with newly diagnosed epithelial ovarian cancer: an ambispective cohort study.Frontiers in nutrition · 2025Article
- Glycemic management in patients with immune-related diabetes mellitus: A scoping review.SAGE open medicine · 2025Review
- Article
- Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells.Journal of ovarian research · 2023Article
- Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells.bioRxiv : the preprint server for biology · 2023Article
- Bidirectional Mendelian randomization study of insulin-related traits and risk of ovarian cancer.Frontiers in endocrinology · 2023Article
- Increased risk of cancer and cancer-related mortality in middle-aged Korean women with prediabetes and diabetes: a population-based study.Epidemiology and health · 2023Article
- Impact of Diabetes on Short-Term and Long-Term Outcomes of Ampullary Adenocarcinoma Patients after Curative Pancreatoduodenectomy.Current oncology (Toronto, Ont.) · 2022Article
- Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.Cancers · 2022Review
- Survival in Advanced Epithelial Ovarian Cancer Associated with Cardiovascular Comorbidities and Type 2 Diabetes Mellitus.Current oncology (Toronto, Ont.) · 2021Article
- Report from the 36th Annual Meeting of the Korean Society of Gynecologic Oncology (KSGO).Journal of gynecologic oncology · 2021Article
- Preoperative low hematocrit is an adverse prognostic biomarker in ovarian cancer.Archives of gynecology and obstetrics · 2021Article
- An Integrated Approach for Cancer Survival Prediction Using Data Mining Techniques.Computational intelligence and neuroscience · 2021Article
- Mortality and glycemic control among patients with diabetes mellitus and uterine or ovarian cancer.Future science OA · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) is associated with poorer outcomes in some cancers. Its effect on ovarian cancer is less clear. We consider the effect of DM on overall survival (OS) and progression free survival (PFS) in patients with epithelial ovarian cancer (EOC).
methodsA retrospective cohort study of 215 patients with EOC diagnosed between 2009 and 2016 was performed. Records were reviewed for standard demographic, pathologic and DM diagnosis data. Cox regression was used to evaluate the relationship between disease status and survival after adjustment for age, body mass index (BMI), parity, stage, grade, histology, debulking status, hypertension (HTN), menopause status and neoadjuant chemotherapy.
resultsPatients with DM (27.97, 95%CI: 23.63 to 32.30) had a significantly shorter OS rates compared to patients without DM (41.01, 95%CI: 38.84 to 43.17). The unadjusted hazard ratio (HR) for the association between OS time and DM was 4.76 (95%CI: 2.99 to 7.59, P < 0.001). Following adjustment for demographic and pathologic variables, the HR was 3.93 (95% CI: 2.01 to 7.68; P < 0.001). The PFS in patients with DM (14.10, 95%CI: 11.76 to 16.44) was significantly shorter compared to patients without DM (28.83, 95%CI: 26.13 to 31.54). The unadjusted HR for PFS and DM was 5.69 (95% CI: 3.05 to 10.61; P < 0.001). After adjustment for demographic and pathologic variables, the HR was 2.73 (95% CI, 1.18 to 6.95; P < 0.001).
conclusionsDM can negatively effect on PFS and OS in EOC patients independent of the effect of other variables.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.